1. Comparison of transvaginal surgery and methotrexate/mifepristone-combined transcervical resection in the treatment of cesarean scar pregnancy
- Author
-
Y-Y, Li, Z-Y, Yin, S, Li, H, Xu, X-P, Zhang, H, Cheng, L, Du, X-Y, Zhou, and B, Zhang
- Subjects
Adult ,Cesarean Section ,Operative Time ,Blood Loss, Surgical ,Length of Stay ,Uterine Artery Embolization ,Pregnancy, Ectopic ,Cicatrix ,Mifepristone ,Methotrexate ,Treatment Outcome ,Pregnancy ,Humans ,Chorionic Gonadotropin, beta Subunit, Human ,Female ,Retrospective Studies - Abstract
To explore the safety and efficiency of transvaginal surgical treatment of cesarean scar pregnancy (CSP).A retrospective analysis of 54 CSP patients that received treatment in our hospital from October 2011 to September 2015 was performed, dividing two groups: Group A (n=34) received transvaginal cesarean scar pregnancy focus clearance surgery while Group B (n=20) received transcervical resection following methotrexate/mifepristone-combined treatment. The basic clinical findings were collected and analyzed, along with the curative effects between the two groups.Differences in age (30.91 ± 4.59 years vs. 31.91 ± 5.53 years) for gravidity (2.97 ± 1.24 times vs. 2.75 ± 1.48 times), cesarean section (1.24 ± 0.43 vs. 1.20 ± 0.41), time interval from last cesarean section (56.53 ± 32.93 months vs. 58.70 ± 39.44 months), menelipsis (51.35 ± 10.90 days vs. 57.85 ± 16.62 days), pre-operative serum-hCG (27953.65 ± 37517.10 mIU/L vs. 17368.24 ± 35094.14 mIU/L), operation time (43.34 ± 12.38 min vs 40.07 ± 16.88 min), menstruation recovery time (1.23 ± 0.53 months vs. 1.55 ± 0.76 months) were not statistically significant (p0.05). The differences in the intraoperative blood loss (43.34 ± 12.38 ml vs. 40.07 ± 16.88 ml), average hospital stay (7.61 ± 2.47 days vs. 12.42 ± 3.64 days), time for β-hCG to return to normal (18.50 ± 8.19 mIU/L vs. 29.00 ± 12.96 mIU/L) between the two groups were statistically significant (p0.05). Group A was significantly lower than Group B.Transvaginal surgery is an effective and relatively safe treatment option for CSP patients.
- Published
- 2017